Why Tempus AI Stock Skyrocketed Nearly 22% Today
It deepened its involvement in a client and peer.
Personalis Reports First Quarter 2023 Financial Results
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights....
Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
Personalis, Inc. (Nasdaq: PSNL) today announced it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial, B-STRONGER-1 (Breast Cancer-Minimal...